Among the 719 patients enrolled in the COPILOTE cohort, 610 had at least 10 years of follow-up (median = 10.0 years, IQR = 10.0–10.1). Others withdrew participation (n = 92) or died (n = 17). Among the 591 patients (96.9%) with clinical response, 561 had at least two HIV-1 RNA measures in the last 18 months. Favourable virological response was seen in 399 (71.1%) participants (Figure S1, available as Supplementary data at JAC Online). Patients' characteristics were similar for the total COPILOTE cohort and the 399 patients in virological success (Table S1). The median number of CD4 and CD8 measures during the last 18 months of follow-up was 5 (IQR = 4–5). Failure to achieve a CD4 response (CD4 >500/mm3) was seen in 132 patients (33.1%), failure to obtain a CD4:CD8 ratio >1 in 306 participants (76.7%) and absence of complete immunological response (combined CD4 and CD4:CD8 ratio measures) in 319 participants (80.0%). The proportion of patients failing to achieve a CD4:CD8 ratio >1 and a complete immunological response were quite closed, analyses found concordant results for both sub-groups (data not shown), and only results for the first (CD4 response) and third (complete immunological response) ones are presented. Table 1 shows demographics, baseline and ART characteristics of patients according to the immunological response. In multivariate analysis, factors independently associated with failure to achieve immunological response were older age, non-immunological response during the first year of follow-up, in addition to some treatment history characteristics (Table 2). A longer duration of treatment interruption was significantly associated with a higher risk of failure of both CD4 and complete immunological responses (Table 2). CD4 response was not associated with number of treatment classes, regimens or lines received. Failure to achieve a complete immunological response was also associated with a higher number of different antiretroviral regimens and lower number of lines of therapy (Table 2). Baseline CD4 count was not associated with the 10 year immunological outcome when taking into account initial first year (month 4, 8 or 12) immunological response.
Clinical, demographic and ART characteristics of the 399 patients with clinical and virological response according to immunological response at 10 years
| . | CD4 response (>500/mm3) . | Complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| failure (N = 132) . | success (N = 267) . | P . | failure (N = 319) . | success (P = 80) . | P . | |||||
| Age (years), median (IQR) | 41.4 | (35.4–48.8) | 36.8 | (32.5–43.0) | <0.0001 | 38.5 | (33.5–45.3) | 38.6 | (33.0–44.7) | 0.54 |
| Male, n (%) | 107 | (81.1) | 214 | (80.1) | 0.829 | 266 | (83.4) | 55 | (68.8) | 0.003 |
| Risk factor for HIV infection, n (%) | 0.006 | 0.388 | ||||||||
| homosexual/bisexual | 49 | (37.1) | 120 | (44.9) | 136 | (42.6) | 33 | (41.3) | ||
| intravenous drug use | 14 | (10.6) | 32 | (12.0) | 37 | (11.6) | 9 | (11.3) | ||
| heterosexual | 42 | (31.8) | 93 | (34.8) | 103 | (32.3) | 32 | (40.0) | ||
| other or unknown | 27 | (20.4) | 22 | (8.2) | 43 | (13.4) | 6 | (7.5) | ||
| CDC stage C, n (%) | 40 | (30.3) | 57 | (21.3) | 0.05 | 81 | (25.4) | 16 | (20.0) | 0.315 |
| Antiretroviral naive, n (%) | 60 | (45.5) | 137 | (51.3) | 0.271 | 159 | (49.8) | 38 | (47.5) | 0.708 |
| HIV RNA (log10 copies/mL), median (IQR) | 4.6 | (3.7–5.3) | 4.6 | (3.7–5.1) | 0.677 | 4.6 | (3.7–5.2) | 4.5 | (3.6–5.2) | 0.528 |
| CD4 cell counts (/mm3), median (IQR) | 168 | (88–295) | 307 | (154–437) | <0.0001 | 238 | (103–389) | 324 | (187–425) | 0.005 |
| CD4 <200/mm3, n (%) | 72 | (55) | 85 | (32) | <0.0001 | 134 | (42) | 23 | (29) | 0.036 |
| CD4 >500/mm3, n (%) | 6 | (5) | 45 | (17) | 0.001 | 38 | (12) | 13 | (17) | 0.279 |
| Antiretroviral number, median (IQR) | 7.5 | (6–10) | 7 | (6–9) | 0.109 | 7 | (6.0–9.0) | 7 | (6.0–8.5) | 0.179 |
| Antiretroviral classes, median (IQR) | 3 | (3–3) | 3 | (2–3) | 0.098 | 3 | (2–3) | 3 | (2–3) | 0.557 |
| Patients with ≥3 antiretroviral classes, n (%) | 104 | (78.8) | 190 | (71.2) | 0.104 | 238 | (74.6) | 56 | (70.0) | 0.403 |
| Duration on PI (months), median (IQR) | 58.7 | (30.8–114.2) | 67.1 | (31.7–113.6) | 0.275 | 64.2 | (31.6–113.5) | 69.4 | (29.0–115.6) | 0.958 |
| Duration on NNRTI (months), median (IQR) | 53.0 | (2.5–93) | 40.5 | (0.0–86.7) | 0.109 | 45.9 | (0.4–88.7) | 62.5 | (0.0–91.5) | 0.601 |
| Number of antiretroviral regimens, median (IQR) | 3 | (2–4) | 3 | (2–4) | 0.142 | 2 | (2–3) | 3 | (2–4) | 0.172 |
| Patients with ≥3 regimens, n (%) | 79 | (59.8) | 137 | (51.3) | 0.107 | 179 | (56.1) | 37 | (46.3) | 0.113 |
| Antiretroviral lines, median (IQR) | 6 | (4–9) | 6 | (4–9) | 0.216 | 6 | (4.0–9.0) | 6 | (4.0–9.0) | 0.988 |
| Duration of treatment lines (months), median (IQR) | 5.6 | (1.1–18.8) | 7.3 | (1.7–20.3) | 0.018 | 6.4 | (1.5–20.0) | 7.0 | (1.3–19.9) | 0.805 |
| Total duration of antiretroviral interruption (months), median (IQR) | 0 | (0.0–1.4) | 0 | (0.0–0.06) | 0.558 | 0 | (0.0–1.2) | 0 | (0.0–0.0) | 0.326 |
| Total duration of antiretroviral interruption (months), mean (SD; range) | 3.7 | (10.1; 0.0–69.8) | 2.7 | (7.0; 0.0–41.8) | ND | 3.4 | (8.9; 0.0–69.8) | 1.4 | (3.5; 0.0–17.7) | ND |
| PI initially prescribed, n (%) | 0.076 | 0.922 | ||||||||
| indinavir ± ritonavir | 66 | (50.0) | 112 | (41.9) | 143 | (44.8) | 35 | (43.8) | ||
| nelfinavir ± ritonavir | 43 | (32.6) | 83 | (31.1) | 102 | (32.0) | 24 | (30.0) | ||
| saquinavir ± ritonavir | 14 | (10.6) | 30 | (11.2) | 35 | (11.0) | 9 | (11.3) | ||
| ritonavir | 20 | (15.2) | 57 | (21.3) | 62 | (19.4) | 15 | (18.8) | ||
| PI combination | 12 | (9.1) | 22 | (8.2) | 28 | (8.8) | 6 | (7.5) | ||
| . | CD4 response (>500/mm3) . | Complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| failure (N = 132) . | success (N = 267) . | P . | failure (N = 319) . | success (P = 80) . | P . | |||||
| Age (years), median (IQR) | 41.4 | (35.4–48.8) | 36.8 | (32.5–43.0) | <0.0001 | 38.5 | (33.5–45.3) | 38.6 | (33.0–44.7) | 0.54 |
| Male, n (%) | 107 | (81.1) | 214 | (80.1) | 0.829 | 266 | (83.4) | 55 | (68.8) | 0.003 |
| Risk factor for HIV infection, n (%) | 0.006 | 0.388 | ||||||||
| homosexual/bisexual | 49 | (37.1) | 120 | (44.9) | 136 | (42.6) | 33 | (41.3) | ||
| intravenous drug use | 14 | (10.6) | 32 | (12.0) | 37 | (11.6) | 9 | (11.3) | ||
| heterosexual | 42 | (31.8) | 93 | (34.8) | 103 | (32.3) | 32 | (40.0) | ||
| other or unknown | 27 | (20.4) | 22 | (8.2) | 43 | (13.4) | 6 | (7.5) | ||
| CDC stage C, n (%) | 40 | (30.3) | 57 | (21.3) | 0.05 | 81 | (25.4) | 16 | (20.0) | 0.315 |
| Antiretroviral naive, n (%) | 60 | (45.5) | 137 | (51.3) | 0.271 | 159 | (49.8) | 38 | (47.5) | 0.708 |
| HIV RNA (log10 copies/mL), median (IQR) | 4.6 | (3.7–5.3) | 4.6 | (3.7–5.1) | 0.677 | 4.6 | (3.7–5.2) | 4.5 | (3.6–5.2) | 0.528 |
| CD4 cell counts (/mm3), median (IQR) | 168 | (88–295) | 307 | (154–437) | <0.0001 | 238 | (103–389) | 324 | (187–425) | 0.005 |
| CD4 <200/mm3, n (%) | 72 | (55) | 85 | (32) | <0.0001 | 134 | (42) | 23 | (29) | 0.036 |
| CD4 >500/mm3, n (%) | 6 | (5) | 45 | (17) | 0.001 | 38 | (12) | 13 | (17) | 0.279 |
| Antiretroviral number, median (IQR) | 7.5 | (6–10) | 7 | (6–9) | 0.109 | 7 | (6.0–9.0) | 7 | (6.0–8.5) | 0.179 |
| Antiretroviral classes, median (IQR) | 3 | (3–3) | 3 | (2–3) | 0.098 | 3 | (2–3) | 3 | (2–3) | 0.557 |
| Patients with ≥3 antiretroviral classes, n (%) | 104 | (78.8) | 190 | (71.2) | 0.104 | 238 | (74.6) | 56 | (70.0) | 0.403 |
| Duration on PI (months), median (IQR) | 58.7 | (30.8–114.2) | 67.1 | (31.7–113.6) | 0.275 | 64.2 | (31.6–113.5) | 69.4 | (29.0–115.6) | 0.958 |
| Duration on NNRTI (months), median (IQR) | 53.0 | (2.5–93) | 40.5 | (0.0–86.7) | 0.109 | 45.9 | (0.4–88.7) | 62.5 | (0.0–91.5) | 0.601 |
| Number of antiretroviral regimens, median (IQR) | 3 | (2–4) | 3 | (2–4) | 0.142 | 2 | (2–3) | 3 | (2–4) | 0.172 |
| Patients with ≥3 regimens, n (%) | 79 | (59.8) | 137 | (51.3) | 0.107 | 179 | (56.1) | 37 | (46.3) | 0.113 |
| Antiretroviral lines, median (IQR) | 6 | (4–9) | 6 | (4–9) | 0.216 | 6 | (4.0–9.0) | 6 | (4.0–9.0) | 0.988 |
| Duration of treatment lines (months), median (IQR) | 5.6 | (1.1–18.8) | 7.3 | (1.7–20.3) | 0.018 | 6.4 | (1.5–20.0) | 7.0 | (1.3–19.9) | 0.805 |
| Total duration of antiretroviral interruption (months), median (IQR) | 0 | (0.0–1.4) | 0 | (0.0–0.06) | 0.558 | 0 | (0.0–1.2) | 0 | (0.0–0.0) | 0.326 |
| Total duration of antiretroviral interruption (months), mean (SD; range) | 3.7 | (10.1; 0.0–69.8) | 2.7 | (7.0; 0.0–41.8) | ND | 3.4 | (8.9; 0.0–69.8) | 1.4 | (3.5; 0.0–17.7) | ND |
| PI initially prescribed, n (%) | 0.076 | 0.922 | ||||||||
| indinavir ± ritonavir | 66 | (50.0) | 112 | (41.9) | 143 | (44.8) | 35 | (43.8) | ||
| nelfinavir ± ritonavir | 43 | (32.6) | 83 | (31.1) | 102 | (32.0) | 24 | (30.0) | ||
| saquinavir ± ritonavir | 14 | (10.6) | 30 | (11.2) | 35 | (11.0) | 9 | (11.3) | ||
| ritonavir | 20 | (15.2) | 57 | (21.3) | 62 | (19.4) | 15 | (18.8) | ||
| PI combination | 12 | (9.1) | 22 | (8.2) | 28 | (8.8) | 6 | (7.5) | ||
ND, not done.
Clinical, demographic and ART characteristics of the 399 patients with clinical and virological response according to immunological response at 10 years
| . | CD4 response (>500/mm3) . | Complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| failure (N = 132) . | success (N = 267) . | P . | failure (N = 319) . | success (P = 80) . | P . | |||||
| Age (years), median (IQR) | 41.4 | (35.4–48.8) | 36.8 | (32.5–43.0) | <0.0001 | 38.5 | (33.5–45.3) | 38.6 | (33.0–44.7) | 0.54 |
| Male, n (%) | 107 | (81.1) | 214 | (80.1) | 0.829 | 266 | (83.4) | 55 | (68.8) | 0.003 |
| Risk factor for HIV infection, n (%) | 0.006 | 0.388 | ||||||||
| homosexual/bisexual | 49 | (37.1) | 120 | (44.9) | 136 | (42.6) | 33 | (41.3) | ||
| intravenous drug use | 14 | (10.6) | 32 | (12.0) | 37 | (11.6) | 9 | (11.3) | ||
| heterosexual | 42 | (31.8) | 93 | (34.8) | 103 | (32.3) | 32 | (40.0) | ||
| other or unknown | 27 | (20.4) | 22 | (8.2) | 43 | (13.4) | 6 | (7.5) | ||
| CDC stage C, n (%) | 40 | (30.3) | 57 | (21.3) | 0.05 | 81 | (25.4) | 16 | (20.0) | 0.315 |
| Antiretroviral naive, n (%) | 60 | (45.5) | 137 | (51.3) | 0.271 | 159 | (49.8) | 38 | (47.5) | 0.708 |
| HIV RNA (log10 copies/mL), median (IQR) | 4.6 | (3.7–5.3) | 4.6 | (3.7–5.1) | 0.677 | 4.6 | (3.7–5.2) | 4.5 | (3.6–5.2) | 0.528 |
| CD4 cell counts (/mm3), median (IQR) | 168 | (88–295) | 307 | (154–437) | <0.0001 | 238 | (103–389) | 324 | (187–425) | 0.005 |
| CD4 <200/mm3, n (%) | 72 | (55) | 85 | (32) | <0.0001 | 134 | (42) | 23 | (29) | 0.036 |
| CD4 >500/mm3, n (%) | 6 | (5) | 45 | (17) | 0.001 | 38 | (12) | 13 | (17) | 0.279 |
| Antiretroviral number, median (IQR) | 7.5 | (6–10) | 7 | (6–9) | 0.109 | 7 | (6.0–9.0) | 7 | (6.0–8.5) | 0.179 |
| Antiretroviral classes, median (IQR) | 3 | (3–3) | 3 | (2–3) | 0.098 | 3 | (2–3) | 3 | (2–3) | 0.557 |
| Patients with ≥3 antiretroviral classes, n (%) | 104 | (78.8) | 190 | (71.2) | 0.104 | 238 | (74.6) | 56 | (70.0) | 0.403 |
| Duration on PI (months), median (IQR) | 58.7 | (30.8–114.2) | 67.1 | (31.7–113.6) | 0.275 | 64.2 | (31.6–113.5) | 69.4 | (29.0–115.6) | 0.958 |
| Duration on NNRTI (months), median (IQR) | 53.0 | (2.5–93) | 40.5 | (0.0–86.7) | 0.109 | 45.9 | (0.4–88.7) | 62.5 | (0.0–91.5) | 0.601 |
| Number of antiretroviral regimens, median (IQR) | 3 | (2–4) | 3 | (2–4) | 0.142 | 2 | (2–3) | 3 | (2–4) | 0.172 |
| Patients with ≥3 regimens, n (%) | 79 | (59.8) | 137 | (51.3) | 0.107 | 179 | (56.1) | 37 | (46.3) | 0.113 |
| Antiretroviral lines, median (IQR) | 6 | (4–9) | 6 | (4–9) | 0.216 | 6 | (4.0–9.0) | 6 | (4.0–9.0) | 0.988 |
| Duration of treatment lines (months), median (IQR) | 5.6 | (1.1–18.8) | 7.3 | (1.7–20.3) | 0.018 | 6.4 | (1.5–20.0) | 7.0 | (1.3–19.9) | 0.805 |
| Total duration of antiretroviral interruption (months), median (IQR) | 0 | (0.0–1.4) | 0 | (0.0–0.06) | 0.558 | 0 | (0.0–1.2) | 0 | (0.0–0.0) | 0.326 |
| Total duration of antiretroviral interruption (months), mean (SD; range) | 3.7 | (10.1; 0.0–69.8) | 2.7 | (7.0; 0.0–41.8) | ND | 3.4 | (8.9; 0.0–69.8) | 1.4 | (3.5; 0.0–17.7) | ND |
| PI initially prescribed, n (%) | 0.076 | 0.922 | ||||||||
| indinavir ± ritonavir | 66 | (50.0) | 112 | (41.9) | 143 | (44.8) | 35 | (43.8) | ||
| nelfinavir ± ritonavir | 43 | (32.6) | 83 | (31.1) | 102 | (32.0) | 24 | (30.0) | ||
| saquinavir ± ritonavir | 14 | (10.6) | 30 | (11.2) | 35 | (11.0) | 9 | (11.3) | ||
| ritonavir | 20 | (15.2) | 57 | (21.3) | 62 | (19.4) | 15 | (18.8) | ||
| PI combination | 12 | (9.1) | 22 | (8.2) | 28 | (8.8) | 6 | (7.5) | ||
| . | CD4 response (>500/mm3) . | Complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| failure (N = 132) . | success (N = 267) . | P . | failure (N = 319) . | success (P = 80) . | P . | |||||
| Age (years), median (IQR) | 41.4 | (35.4–48.8) | 36.8 | (32.5–43.0) | <0.0001 | 38.5 | (33.5–45.3) | 38.6 | (33.0–44.7) | 0.54 |
| Male, n (%) | 107 | (81.1) | 214 | (80.1) | 0.829 | 266 | (83.4) | 55 | (68.8) | 0.003 |
| Risk factor for HIV infection, n (%) | 0.006 | 0.388 | ||||||||
| homosexual/bisexual | 49 | (37.1) | 120 | (44.9) | 136 | (42.6) | 33 | (41.3) | ||
| intravenous drug use | 14 | (10.6) | 32 | (12.0) | 37 | (11.6) | 9 | (11.3) | ||
| heterosexual | 42 | (31.8) | 93 | (34.8) | 103 | (32.3) | 32 | (40.0) | ||
| other or unknown | 27 | (20.4) | 22 | (8.2) | 43 | (13.4) | 6 | (7.5) | ||
| CDC stage C, n (%) | 40 | (30.3) | 57 | (21.3) | 0.05 | 81 | (25.4) | 16 | (20.0) | 0.315 |
| Antiretroviral naive, n (%) | 60 | (45.5) | 137 | (51.3) | 0.271 | 159 | (49.8) | 38 | (47.5) | 0.708 |
| HIV RNA (log10 copies/mL), median (IQR) | 4.6 | (3.7–5.3) | 4.6 | (3.7–5.1) | 0.677 | 4.6 | (3.7–5.2) | 4.5 | (3.6–5.2) | 0.528 |
| CD4 cell counts (/mm3), median (IQR) | 168 | (88–295) | 307 | (154–437) | <0.0001 | 238 | (103–389) | 324 | (187–425) | 0.005 |
| CD4 <200/mm3, n (%) | 72 | (55) | 85 | (32) | <0.0001 | 134 | (42) | 23 | (29) | 0.036 |
| CD4 >500/mm3, n (%) | 6 | (5) | 45 | (17) | 0.001 | 38 | (12) | 13 | (17) | 0.279 |
| Antiretroviral number, median (IQR) | 7.5 | (6–10) | 7 | (6–9) | 0.109 | 7 | (6.0–9.0) | 7 | (6.0–8.5) | 0.179 |
| Antiretroviral classes, median (IQR) | 3 | (3–3) | 3 | (2–3) | 0.098 | 3 | (2–3) | 3 | (2–3) | 0.557 |
| Patients with ≥3 antiretroviral classes, n (%) | 104 | (78.8) | 190 | (71.2) | 0.104 | 238 | (74.6) | 56 | (70.0) | 0.403 |
| Duration on PI (months), median (IQR) | 58.7 | (30.8–114.2) | 67.1 | (31.7–113.6) | 0.275 | 64.2 | (31.6–113.5) | 69.4 | (29.0–115.6) | 0.958 |
| Duration on NNRTI (months), median (IQR) | 53.0 | (2.5–93) | 40.5 | (0.0–86.7) | 0.109 | 45.9 | (0.4–88.7) | 62.5 | (0.0–91.5) | 0.601 |
| Number of antiretroviral regimens, median (IQR) | 3 | (2–4) | 3 | (2–4) | 0.142 | 2 | (2–3) | 3 | (2–4) | 0.172 |
| Patients with ≥3 regimens, n (%) | 79 | (59.8) | 137 | (51.3) | 0.107 | 179 | (56.1) | 37 | (46.3) | 0.113 |
| Antiretroviral lines, median (IQR) | 6 | (4–9) | 6 | (4–9) | 0.216 | 6 | (4.0–9.0) | 6 | (4.0–9.0) | 0.988 |
| Duration of treatment lines (months), median (IQR) | 5.6 | (1.1–18.8) | 7.3 | (1.7–20.3) | 0.018 | 6.4 | (1.5–20.0) | 7.0 | (1.3–19.9) | 0.805 |
| Total duration of antiretroviral interruption (months), median (IQR) | 0 | (0.0–1.4) | 0 | (0.0–0.06) | 0.558 | 0 | (0.0–1.2) | 0 | (0.0–0.0) | 0.326 |
| Total duration of antiretroviral interruption (months), mean (SD; range) | 3.7 | (10.1; 0.0–69.8) | 2.7 | (7.0; 0.0–41.8) | ND | 3.4 | (8.9; 0.0–69.8) | 1.4 | (3.5; 0.0–17.7) | ND |
| PI initially prescribed, n (%) | 0.076 | 0.922 | ||||||||
| indinavir ± ritonavir | 66 | (50.0) | 112 | (41.9) | 143 | (44.8) | 35 | (43.8) | ||
| nelfinavir ± ritonavir | 43 | (32.6) | 83 | (31.1) | 102 | (32.0) | 24 | (30.0) | ||
| saquinavir ± ritonavir | 14 | (10.6) | 30 | (11.2) | 35 | (11.0) | 9 | (11.3) | ||
| ritonavir | 20 | (15.2) | 57 | (21.3) | 62 | (19.4) | 15 | (18.8) | ||
| PI combination | 12 | (9.1) | 22 | (8.2) | 28 | (8.8) | 6 | (7.5) | ||
ND, not done.
Factors associated with failure to achieve CD4 response (CD4 >500/mm3) or complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) in patients with clinical and virological success 10 years after starting a PI-containing cART (final multivariate logistic regression model)—ANRS CO8 COPILOTE cohort
| Factor . | OR (95% CI) . | P . |
|---|---|---|
| Failure to achieve CD4 response (CD4 >500/mm3) | ||
| age at month 0 (≥40 versus <40 years) | 2.55 (1.57–4.12) | <0.001 |
| CD4 cell counts at month 4 (≤500 versus >500/mm3) | 2.79 (1.21–6.42) | 0.016 |
| CD4 cell counts at month 12 (≤500 versus >500/mm3) | 3.56 (1.81–6.99) | <0.001 |
| total duration of ART interruption (≥3 versus <3 months) | 2.32 (1.17–4.58) | 0.016 |
| Failure to achieve complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) | ||
| CD4:CD8 ratio at month 8 (≤0.8 versus >0.8) | 6.14 (2.21–17.1) | <0.001 |
| CD4:CD8 ratio at month 12 (≤0.8 versus >0.8) | 5.53 (2.18–14.0) | <0.001 |
| total duration of ART interruption (≥3 versus <3 months) | 4.44 (1.41–13.9) | 0.011 |
| number of antiretroviral regimens (≥3 versus <3) | 2.97 (1.31–6.75) | 0.009 |
| number of treatment lines (4–6 versus 0–4) | 0.33 (0.14–0.75) | |
| number of treatment lines (6–9 versus 0–4) | 0.58 (0.19–1.77) | 0.015 |
| number of treatment lines (≥10 versus 0–4) | 0.19 (0.06–0.62) | |
| Factor . | OR (95% CI) . | P . |
|---|---|---|
| Failure to achieve CD4 response (CD4 >500/mm3) | ||
| age at month 0 (≥40 versus <40 years) | 2.55 (1.57–4.12) | <0.001 |
| CD4 cell counts at month 4 (≤500 versus >500/mm3) | 2.79 (1.21–6.42) | 0.016 |
| CD4 cell counts at month 12 (≤500 versus >500/mm3) | 3.56 (1.81–6.99) | <0.001 |
| total duration of ART interruption (≥3 versus <3 months) | 2.32 (1.17–4.58) | 0.016 |
| Failure to achieve complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) | ||
| CD4:CD8 ratio at month 8 (≤0.8 versus >0.8) | 6.14 (2.21–17.1) | <0.001 |
| CD4:CD8 ratio at month 12 (≤0.8 versus >0.8) | 5.53 (2.18–14.0) | <0.001 |
| total duration of ART interruption (≥3 versus <3 months) | 4.44 (1.41–13.9) | 0.011 |
| number of antiretroviral regimens (≥3 versus <3) | 2.97 (1.31–6.75) | 0.009 |
| number of treatment lines (4–6 versus 0–4) | 0.33 (0.14–0.75) | |
| number of treatment lines (6–9 versus 0–4) | 0.58 (0.19–1.77) | 0.015 |
| number of treatment lines (≥10 versus 0–4) | 0.19 (0.06–0.62) | |
Variables not significant: CD4 cell counts at month 0 and month 8, CD4:CD8 ratio at month 0 and month 4, HIV RNA at baseline and during follow-up, CDC stage, other ART characteristics and antiretroviral naive. See Table 1.
Factors associated with failure to achieve CD4 response (CD4 >500/mm3) or complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) in patients with clinical and virological success 10 years after starting a PI-containing cART (final multivariate logistic regression model)—ANRS CO8 COPILOTE cohort
| Factor . | OR (95% CI) . | P . |
|---|---|---|
| Failure to achieve CD4 response (CD4 >500/mm3) | ||
| age at month 0 (≥40 versus <40 years) | 2.55 (1.57–4.12) | <0.001 |
| CD4 cell counts at month 4 (≤500 versus >500/mm3) | 2.79 (1.21–6.42) | 0.016 |
| CD4 cell counts at month 12 (≤500 versus >500/mm3) | 3.56 (1.81–6.99) | <0.001 |
| total duration of ART interruption (≥3 versus <3 months) | 2.32 (1.17–4.58) | 0.016 |
| Failure to achieve complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) | ||
| CD4:CD8 ratio at month 8 (≤0.8 versus >0.8) | 6.14 (2.21–17.1) | <0.001 |
| CD4:CD8 ratio at month 12 (≤0.8 versus >0.8) | 5.53 (2.18–14.0) | <0.001 |
| total duration of ART interruption (≥3 versus <3 months) | 4.44 (1.41–13.9) | 0.011 |
| number of antiretroviral regimens (≥3 versus <3) | 2.97 (1.31–6.75) | 0.009 |
| number of treatment lines (4–6 versus 0–4) | 0.33 (0.14–0.75) | |
| number of treatment lines (6–9 versus 0–4) | 0.58 (0.19–1.77) | 0.015 |
| number of treatment lines (≥10 versus 0–4) | 0.19 (0.06–0.62) | |
| Factor . | OR (95% CI) . | P . |
|---|---|---|
| Failure to achieve CD4 response (CD4 >500/mm3) | ||
| age at month 0 (≥40 versus <40 years) | 2.55 (1.57–4.12) | <0.001 |
| CD4 cell counts at month 4 (≤500 versus >500/mm3) | 2.79 (1.21–6.42) | 0.016 |
| CD4 cell counts at month 12 (≤500 versus >500/mm3) | 3.56 (1.81–6.99) | <0.001 |
| total duration of ART interruption (≥3 versus <3 months) | 2.32 (1.17–4.58) | 0.016 |
| Failure to achieve complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) | ||
| CD4:CD8 ratio at month 8 (≤0.8 versus >0.8) | 6.14 (2.21–17.1) | <0.001 |
| CD4:CD8 ratio at month 12 (≤0.8 versus >0.8) | 5.53 (2.18–14.0) | <0.001 |
| total duration of ART interruption (≥3 versus <3 months) | 4.44 (1.41–13.9) | 0.011 |
| number of antiretroviral regimens (≥3 versus <3) | 2.97 (1.31–6.75) | 0.009 |
| number of treatment lines (4–6 versus 0–4) | 0.33 (0.14–0.75) | |
| number of treatment lines (6–9 versus 0–4) | 0.58 (0.19–1.77) | 0.015 |
| number of treatment lines (≥10 versus 0–4) | 0.19 (0.06–0.62) | |
Variables not significant: CD4 cell counts at month 0 and month 8, CD4:CD8 ratio at month 0 and month 4, HIV RNA at baseline and during follow-up, CDC stage, other ART characteristics and antiretroviral naive. See Table 1.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
